Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | PLK4 | O00444 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828520 | 1.00 | SYK (0.37) | SYKJUNNFKB1NFKB2RELA | |
| SCHEMBL15120617 | 0.82 | SYK (0.37) | SYKJUNNFKB1NFKB2RELA | |
| SCHEMBL1341445 | 0.82 | MEN1 (0.39) | SYKJUNNFKB1NFKB2RELA | |
| Lithium SCHEMBL30171289 | 0.80 | MEN1 (0.38) | SYKJUNNFKB1NFKB2RELA | |
| SCHEMBL17194940 | 0.80 | SYK (0.39) | SYKJUNNFKB1NFKB2RELA | |
| SCHEMBL28719374 | 0.80 | MEN1 (0.38) | SYKJUNNFKB1NFKB2RELA | |
| SCHEMBL15689372 | 0.80 | SYK (0.50) | SYKJUNNFKB1NFKB2RELA | |
| Lithium Ion SCHEMBL30079578 | 0.78 | SYK (0.35) | SYKJUNNFKB1NFKB2RELA | |
| Lithium Ion SCHEMBL22288327 | 0.78 | SYK (0.35) | SYKJUNNFKB1NFKB2RELA | |
| SCHEMBL1343778 | 0.75 | NPSR1 (0.45) | SYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108675-A | Preparation method of 4, 6-dichloro-N- (methyl-d 3) -3-pyridazine formamide | 上海工程技术大学 | 2024-05-31 | — | — | CN | claimed |
| EP-4551560-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | Huyabio International, LLC (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024165000-A1 | PYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海华汇拓医药科技有限公司 | 2024-08-15 | — | — | WO | disclosed |
| US-20240246944-A1 | AMINO HETEROARYL COMPOUNDS AND COMPOSITIONS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-118108675-A | Preparation method of 4, 6-dichloro-N- (methyl-d 3) -3-pyridazine formamide | 上海工程技术大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-118108675-A | Preparation method of 4, 6-dichloro-N- (methyl-d 3) -3-pyridazine formamide | 上海工程技术大学 | 2024-05-31 | — | — | CN | disclosed |
| WO-2024088282-A1 | PYRAZINAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF AS TYK2 INHIBITOR | 浙江华海药业股份有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-117083268-A | Amino heteroaryl compounds and compositions | 安锐生物医药科技(广州)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023177591-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | HUYABIO INTERNATIONAL, LLC | 2023-09-14 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022268119-A1 | SULFOXIMINE COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | ESKER THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | TYK2, JAK1, PDXK | SYK 246/4885JUN 1888/4885NFKB1 1377/4885 |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | SYK 159/4885JUN 2365/4885NFKB1 1571/4885 |
| US-20240246944-A1 | AMINO HETEROARYL COMPOUNDS AND COMPOSITIONS | TYK2, JAK3, PTK2B | SYK 24/4885JUN 1563/4885NFKB1 650/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | SYK 287/4885JUN 1801/4885NFKB1 1169/4885 |
| US-20230286948-A1 | HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR | WDR5, WDR1, WDR3 | SYK 3624/4885JUN 1489/4885NFKB1 2888/4885 |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | SYK 91/4885JUN 2235/4885NFKB1 489/4885 |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | SYK 159/4885JUN 2365/4885NFKB1 1571/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | SYK 340/4885JUN 1741/4885NFKB1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.